Undifferentiated Oedema — Written Clinical Reasoning

SAQ 1 — Integrated Diagnostic Approach to the Complex Oedematous Patient (20 marks, 30 minutes)

Prompt: Outline your integrated diagnostic approach to Mr Whitfield's presentation, addressing: (a) the Starling forces framework and the mechanisms contributing to his oedema; (b) the interpretation of the NT-proBNP, the SAAG, and the urinalysis in his clinical context; (c) the relative contributions of the heart failure, the cirrhosis, the renal protein loss, and the amlodipine, and how you discriminate them; (d) the immediate management in the first 48 hours, including the diuretic strategy and the drugs to review; (e) the role of the SGLT2 inhibitor (dapagliflozin) and the ACE inhibitor in his long-term cardiac management; and (f) the common exam trap in this patient. [1]

Model Answer

(a) Starling forces framework and the mechanisms (4 marks): [1]

The Starling forces govern the movement of fluid across the capillary wall: the capillary hydrostatic pressure (pushing fluid out), the plasma oncotic pressure (pulling fluid back, generated by albumin), the capillary permeability, and the lymphatic drainage. The revised Starling model emphasises the endothelial glycocalyx layer and the principle that under normal physiology there is no significant venular reabsorption, with the filtered fluid returned almost entirely by the lymphatics [2]. A fifth mechanism — the renal retention of sodium and water in response to a perceived underfill of the arterial circulation — is the dominant mechanism in heart failure and cirrhosis.

In Mr Whitfield, four mechanisms operate simultaneously. The cardiac mechanism (the raised JVP, the crackles, the gallop, the EF 34 per cent) causes the sodium retention and the raised venous hydrostatic pressure. The hepatic mechanism (the cirrhosis, the ascites, the hypoalbuminaemia) causes the portal hypertension and the reduced oncotic pressure. The renal mechanism (the 1+ proteinuria, the rising creatinine) suggests a mild protein leak and a reduced sodium excretion from the diabetic nephropathy. The drug mechanism (the amlodipine 10 mg daily) contributes the arteriolar vasodilatory oedema. [1]

(b) Interpretation of the investigations (4 marks): [1]

The NT-proBNP of 2100 pg per mL is above the PRIDE age-stratified rule-in cutpoint of 900 pg per mL for a patient over 50, which supports the cardiac contribution to his oedema and dyspnoea [6]. However, I interpret it in the clinical context — he has cirrhosis, an acute decompensation, and a rising creatinine, all of which can elevate the peptide, and the value does not by itself quantify the cardiac contribution.

The SAAG is calculated as the serum albumin minus the ascitic albumin: 28 minus 14 equals 14 g per litre. A SAAG of 11 g per litre or above indicates portal hypertension with an accuracy of approximately 97 per cent, confirming the portal hypertension as the mechanism of his ascites [4]. The ascitic neutrophil count of 30 per microlitre is below 250, which excludes the spontaneous bacterial peritonitis.

The urinalysis of 1+ proteinuria is mild and is most consistent with the diabetic nephropathy or the congestive cardiac failure rather than a primary nephrotic syndrome — the albumin of 28 g per litre, while low, is not low enough to indicate a heavy protein leak as the sole cause. I would quantify the proteinuria with a spot urine protein-to-creatinine ratio to confirm it is sub-nephrotic. [1]

(c) Discriminating the four mechanisms (4 marks): [1]

I do not try to separate the four mechanisms at the first assessment — I address them in parallel and reassess. The cardiac component (the dominant cause given the raised JVP to the jaw, the crackles, the gallop, and the NT-proBNP of 2100) is addressed with the cautious intravenous diuresis and the optimisation of the four pillars of the heart failure therapy. The hepatic component (the portal hypertension with the SAAG of 14 and the ascites) is addressed with the spironolactone (already on it) and the consideration of the large-volume paracentesis if the ascites is tense and symptomatic. The renal component (the mild proteinuria, the rising creatinine) is monitored and the ACE inhibitor is continued (or held briefly if the creatinine rises by more than 30 per cent). The drug component (the amlodipine 10 mg daily) is addressed by the dose reduction or the discontinuation — the amlodipine is contributing to the peripheral oedema and is not an evidence-based therapy for the heart failure. [1]

(d) Immediate management in the first 48 hours (4 marks): [1]

The immediate management begins with the ABCDE assessment and the cautious diuresis. Because the creatinine is already elevated (145 from the baseline 110), I do not give a large bolus of the furosemide — I increase the furosemide to 120 mg daily (orally, or intravenously if the gut oedema is suspected) and reassess the weight, the JVP, the crackles, the renal function, and the electrolytes at 24 to 48 hours. The target weight loss in a patient with both the peripheral oedema and the ascites is up to 1 kg per day (the cirrhotic target is 0.5 kg per day without the peripheral oedema and 1 kg per day with it, but the cardiac component allows the slightly more aggressive diuresis). I check the sodium (already 130, the dilutional hyponatraemia — I restrict the free water if the sodium falls further). I stop or reduce the amlodipine. I continue the four pillars of the heart failure therapy (the bisoprolol, the ramipril, the spironolactone, the dapagliflozin) — the SGLT2 inhibitor is particularly valuable because it causes a mild diuresis and a reduction in the heart failure hospitalisations. I monitor for the hepatorenal syndrome (the rising creatinine that does not respond to the diuresis and the albumin). I consider the large-volume paracentesis with the albumin replacement (6 to 8 g per litre removed) if the ascites is tense and symptomatic, to relieve the discomfort and the respiratory compromise. [1]

(e) The SGLT2 inhibitor and the ACE inhibitor in the long-term cardiac management (2 marks): [1]

The dapagliflozin (an SGLT2 inhibitor) is one of the four pillars of the guideline-directed therapy for the heart failure with reduced ejection fraction, as established by the 2021 ESC Heart Failure Guidelines [6]. It reduces the heart failure hospitalisations and the cardiovascular mortality, it causes a mild osmotic diuresis and a reduction in the preload, and it is renoprotective in the diabetic kidney disease. It should be continued unless there is a contraindication (the eGFR below the threshold, the volume depletion, the diabetic ketoacidosis). The ramipril (an ACE inhibitor) is another of the four pillars and should be continued (or uptitrated to the target dose) unless the creatinine rises by more than 30 per cent or the potassium exceeds 5.5 mmol per litre. The four pillars together reduce the oedema by improving the ventricular function and the sodium excretion over the weeks to the months.

(f) The common exam trap (2 marks): [1]

The trap is the anchoring error — stopping at the diagnosis of the heart failure and missing the cirrhosis, the rising creatinine (the early hepatorenal syndrome), the drug-induced oedema from the amlodipine, and the mild proteinuria that may represent the diabetic nephropathy. The registrar who treats only with the uptitration of the furosemide has missed the SAAG (which confirms the portal hypertension), the amlodipine (which is contributing to the peripheral oedema), and the hepatorenal risk (which limits the diuresis). The integrated approach — the cardiac, the hepatic, the renal, and the drug — is what keeps the complex oedematous patient safe. The second trap is the over-diuresis — the rising creatinine and the dilutional hyponatraemia are the early warnings, and the registrar who pushes the diuresis without monitoring the renal function precipitates the hepatorenal syndrome. [1]

SAQ 2 — The Serum-Ascites Albumin Gradient and the Drug-Induced Oedema (10 marks)

Prompt: A junior doctor asks you to explain: (a) the serum-ascites albumin gradient (SAAG), how it is calculated and interpreted, and why it has replaced the transudate-exudate classification; (b) the mechanism and the management of the dihydropyridine calcium channel blocker-induced oedema; and (c) why diuretics are ineffective and potentially harmful in the amlodipine-induced oedema. [1]

Model Answer

(a) The SAAG (4 marks): [1]

The serum-ascites albumin gradient (SAAG) is the difference between the serum albumin and the ascitic fluid albumin: SAAG equals serum albumin minus ascitic fluid albumin. A SAAG of 11 g per litre or above indicates portal hypertension with an accuracy of approximately 97 per cent, and the causes include the cirrhosis, the heart failure (including the constrictive pericarditis and the restrictive cardiomyopathy, where the right heart congestion raises the hepatic sinusoidal pressure), and the Budd-Chiari syndrome. A SAAG below 11 g per litre indicates a non-portal cause — the peritoneal carcinomatosis, the tuberculous peritonitis, the nephrotic syndrome, the pancreatic ascites, and the chylous ascites. [1]

The SAAG has replaced the transudate-exudate classification because the latter, based on the ascitic fluid total protein, was correct only 55.6 per cent of the time in the Runyon study of 901 paired samples, whereas the SAAG was correct in 96.7 per cent [4]. The transudate-exudate concept should be discarded in the classification of the ascites. The cell count (a neutrophil count above 250 per microlitre indicates the spontaneous bacterial peritonitis) is the other mandatory result from the diagnostic ascitic tap.

(b) The mechanism and the management of the dihydropyridine CCB-induced oedema (3 marks): [1]

The dihydropyridine calcium channel blockers (amlodipine, nifedipine, felodipine) cause the peripheral oedema by the preferential arteriolar vasodilatation that goes unmatched in the venous circulation [3]. The arteriolar vasodilatation raises the capillary hydrostatic pressure (the precapillary pressure is higher) and drives the fluid into the interstitium. The oedema is a local vasodilatory phenomenon, not a systemic fluid retention — which is the key to the management. The management options are the dose reduction, the switch to a different agent (lercanidipine has less oedema because of its greater vascular selectivity; the non-dihydropyridines such as verapamil and diltiazem have a different mechanism and cause less oedema), the addition of an ACE inhibitor or an ARB (the venodilatation balances the arteriolar vasodilatation and reduces the capillary pressure mismatch), or the discontinuation and the use of a different antihypertensive class. The oedema is dose-dependent and more common in the women, and it is worse with the standing posture.

(c) Why diuretics are ineffective in the amlodipine-induced oedema (3 marks): [1]

The diuretics are ineffective and potentially harmful in the amlodipine-induced oedema because the mechanism is the capillary pressure mismatch, not the volume overload. The diuretic reduces the plasma volume and the intravascular pressure, but it does not correct the arteriolar-venous imbalance — and by reducing the plasma volume further, it may worsen the problem (the RAAS is activated, the renal perfusion falls, and the creatinine may rise). The correct management is to address the mechanism — the dose reduction, the switch, or the addition of the venodilator — not to add a diuretic [3]. The registrar who reaches for the furosemide in the amlodipine oedema has misunderstood the mechanism and will make the patient worse. The corollary is that the diuretics are effective in the cardiac, the hepatic, and the renal oedema (where the sodium and water retention is the dominant mechanism) but not in the drug-induced vasodilatory oedema or the lymphoedema (where the protein-rich interstitium is the problem).